Emerging drugs for non-alcoholic steatohepatitis

Expert Opinion on Emerging Drugs

Volumn 18, Issue 3, 2013, Pages 279-290

  Tomeno, Wataru ^a   Yoneda, Masato ^a   Imajo, Kento ^a   Ogawa, Yuji ^a   Kessoku, Takaomi ^a   Saito, Satoru ^a   Eguchi, Yuichiro ^b   Nakajima, Atsushi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

Clinical trial; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Pharmacologic therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; BLX 1002; CHENODEOXYCHOLIC ACID; GFT 505; GRMD 02; ICOSAPENTAENOIC ACID; INSULIN SENSITIZING AGENT; IPRAGLIFLOZIN; MERCAPTAMINE; MITOQUINONE; MONOCLONAL ANTIBODY CD3; NANOVESON; OBETICHOLIC ACID; OLTIPRAZ; OXIDIZING AGENT; PIOGLITAZONE; ROSIGLITAZONE; RP 103; SITAGLIPTIN; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADVERSE OUTCOME; ANTIANGIOGENIC THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPID PEROXIDATION; LIVER BIOPSY; LIVER CELL CARCINOMA; METABOLIC SYNDROME X; NEOPLASM; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PREVALENCE; REVIEW;

EID: 84883162387     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2013.811232     Document Type: Review

References (99)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346(16):1221-31
2. Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006;40(Suppl 1):S11-16
3. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004;24(1):3-20
4. Mori S, Yamasaki T, Sakaida I, et al. Hepatocellular carcinoma with nonalcoholic steatohepatitis. J Gastroenterol 2004;39(4):391-6
5. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;131:1249-53
6. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-9
7. Baumeister SE, Volzke H, Marchall P, et al. Impact of fatty liver disease on healthcare utilization and costs in a general population: A 5-year observation. Gastroenterology 2008;134:85-94
8. Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: A pilot study. Am J Gastroenterol 2005;100:1072-81
9. Suzuki A, Lindor K, St Saver J, et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005;43(6):1060-6
10. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: An update. Obes Rev 2010;11(6):430-45
11. Mehta K, Van Thiel DH, Shah N, et al. Nonalcoholic fatty liver disease: Pathogenesis and the role of anti-oxidants. Nutr Rev 2002;60:289-93
12. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85
13. Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-90
14. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23
15. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009;49:1017-44
16. Augulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-54
17. Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42(1):132-8
18. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005;129:113-21
19. El-Seraq HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4(3):369-80
20. Miller ER III, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: High dose vitamin E supplementation may increase all cause mortality. Ann Intern Med 2005;142:37-46
21. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
22. Belfort R, Harrison SA, Brown K, et al. A placebo controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307
23. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-84
24. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011;34(4):916-22
25. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008;134:1682-98
26. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese leptin-deficient mice. Nat Med 2000;6:998-1003
27. Bugianesi E, Genticore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90
28. Haukeland JW, Konopski Z, Eggesbo HB, et al. Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial. Scand J Gastroenterol 2009;44:853-60
29. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA 2011;305:1659-39
30. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50
31. Chatrath H, Vuppalamchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 2012;32:22-9
32. Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008;57:1711-18
33. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, et al. A pilot study of atorvastatin treatment in dyslipidemia, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006;23:1643-7
34. Nelson A, Torres DM, Morgan AE, et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 2009;43:990-4
35. Nozaki Y, Fujita K, Yoneda M, et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 2009;51:548-56
36. Yoneda M, Fujita K, Nozaki Y, et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. Hepatol Res 2010;40:613-21
37. Park H, Shima T, Yamaguchi K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011;46:101-7
38. Lindor KD, Kowdley KV, Heathocote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial. Hepatology 2004;39:770-8
39. Leuschner UF, Lindenthal B, Hermann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: A double-blind, randomized, placebo-controlled trial. Hepatology 2010;52:472-9
40. Dufour JF, Oneta CM, Gonvers JJ, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006;4:1537-43
41. Balmer ML, Siegrist K, Zimmermann A, et al. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int 2009;29:1184-8
42. Nonalcoholic Steatohepatitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017. Published on December 8, 2010 by GlobalData
43. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21
44. Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344-53
45. Yoneda M, Yoneda M, Mawatari H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008;40(5):371-8
46. Suzuki K, Yoneda M, Imajo K, et al. Transient elastography for monitoring the fibrosis of non-alcoholic fatty liver disease for 4 years. Hepatol Res 2013;published online 7 January 2013; doi: 10.1111/hepr.12039
47. Chen J, Talwalkar JA, Yin M, et al. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011;259:749-56
48. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92
49. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (Fibro Test-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:6
50. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-7
51. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-25
52. Feldstein AE, Wieckowska A, Lopez R, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology 2009;50:1072-8
53. Day C, James O. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998;114:842-5
54. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: Pld questions and new insights. Science 2011;332:1519-23
55. Ochi H, Abraham M, Ishikawa H, et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25-LAP+ T cells. Nat Med 2006;12(6):627-35
56. Mizrahi M, Lalazar G, Ilan Y, et al. Oral administration of anti-CD3 MAb to patients with NASH is safe, promotes regulatory T cells, decreases liver enzymes, and alleviates insulin resistance: Results of a phase 2a blinded placebo-controlled trial [abstract 117]. The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (The Liver Meeting 2011); 4 - 8 November 2011; San Francisco
57. Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl- chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002;45(17):3569-72
58. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009;89(1):147-91
59. Adirini L, Pruzanski M, Shapiro D, et al. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012;17:988-97
60. Sanyal A, Mudaliar S, Henry R, et al. A new therapy for nonalcoholic fatty liver disease and diabetes? INT-747 - The first FXR hepatic therapeutic study [abstract 183]. The 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (The Liver Meeting 2009); 30 October - 3 November 2009; Boston
61. Available from: Http://www.clinicaltrials. gov/ct2/show/NCT01265498 [Last accessed 27 May 2013
62. Available from: Http://www.ds-pharma. com/rd/clinical/pipeline-profile. html[Last accessed 27 May 2013
63. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005;54:2460-70
64. Reilly SM, Lee CH. PPAR delta as a therapeutic target in metabolic disease. FEBS Lett 2008;582:26-31
65. Hanf R, Darteli R, Hum DW, et al. GFT505 efficacy and safety in healthy volunteers and patients suffering from atherogenic dyslipidemia. Diabetes 2010;59(Suppl 1):A185
66. Cariou B, Zair Y, Steals B, et al. Effects of the new dual PPARa/d agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011;34:2008-14
67. Available from: Http://www.clinicaltrials. gov/ct2/show/NCT01694849 [Last accessed 27 May 2013
68. Bucher HC, Hengstler P, Schindler C, et al. N-3 polyunsaturated fatty acids in coronary heart disease: A meta-analysis of randomized controlled trials. Am J Med 2002;112:298-304
69. Capanni M, Calella F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: A pilot study. Aliment Pharmacol Ther 2006;23:1143-51
70. Svegliati-Baroni G, Candelaresi C, Saccomanno S, et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: Role of peroxisome proliferator-activated receptor-a and n-3 polyunsaturated fatty liver acid treatment on liver injury. Am J Pathol 2006;169:846-60
71. Tanaka N, Sano K, Horiuchi A, et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008;42(4):413-18
72. Available from: Http://www.clinicaltrials. gov/ct2/show/NCT01154985 [Last accessed 27 May 2013
73. Liu RM, Gaston Pravia KA. Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis. Free Radic Biol Med 2010;48:1-15
74. Maher P, Lewerenz J, Lozano C, et al. A novel approach to enhancing cellular glutathione levels. J Neurochem 2008;107:690-700
75. Available from: Http://ir.raptorpharma.com/releasedetail.cfm?ReleaseID= 686051 [Last accessed 27 May 2013
76. Dohil R, Schmeltzer S, Cabrera BL, et al. Enteric-coated cysteamine for the treatment of pediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011;33:1036-44
77. Available from: Http://www.clinicaltrials. gov/ct2/show/NCT01529268 [Last accessed 27 May 2013
78. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 2007;47:629-56
79. Gane EJ, Weilert F, Orr DW, et al. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int 2010;30(7):1019-26
80. Begriche K, Igoudjil A, Pessayre D, et al. Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it. Mitochondrion 2003;6:1-28
81. Available from: Http://www.clinicaltrials. gov/ct2/show/NCT01167088 [Last accessed 27 May 2013
82. Dey D, Pandey B, Nag A, et al. Amino acid conjugated, orally active, novel anti-diabetic compound BLX-1002 has no affinity to PPARg. Diabetes 2004;53(Suppl 2):A483
83. Zhang F, Dey D, Branstorm R, et al. BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner. Am J Physiol Cell Physiol 2009;296:C346-54
84. Narayanan D, Vijayaraj D, Kulkarni NM, et al. Efficacy of BLX-1002 in animal models of non-alcoholic fatty liver disease and dyslipidemia [abstract P1150]. 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011); 30 March - 3April 2011; Berlin
85. Brools SC III, Brooks JS, Lee WH, et al. Therapeutic potential of dithiolethiones for hepatic diseases. Pharmacol Ther 2009;124(1):31-43
86. Hwahng SH, Ki SH, Bae EJ, et al. Role of adenosine monophosphate- activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology 2009;49(6):1913-25
87. Available from: Http://www.clinicaltrials. gov/ct2/show/NCT01373554 [Last accessed 27 May 2013
88. Kurosaki E, Takasu T, Yamazaki S, et al. Ipraglifozin (ASP1941), a novel SGLT2 inhibitor, demonstrates beneficial effects on nonalcoholic fatty liver disease in animal models [abstract P998]. 72nd Annual Meeting and Scientific Sessions of the American Diabetes Association; 8 - 12 June 2012; Philadelphia
89. Coulon SH, Heindryckx F, Colle I, et al. Treatment with anti-vascular endothelial growth factor receptor 2 (aVEGFR2) antibodies attenuates steatosis and inflammation in a diet-induced mouse model for non-alcoholic steatohepatitis (NASH) [abstract 248]. 63rd Ann Meet AASLD; Boston; 2012
90. Traber PG, Zomer E. Galectin-3 targeting drugs inhibit multiple pathological pathways leading to improvement of non-alcoholic steatohepatitis (NASH) [abstract 1436]. The 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (The Liver Meeting 2012); 9 - 13 November2012; Boston
91. Available from: Http://ir.isispharm.com/ phoenix.zhtml?c=222170&p= irolnewsArticle& id=1639873 [Last accessed 27 May 2013
92. Available from: Http://www.phynova. com/Research-Development- ProductPipeline.asp#PYN22 [Last accessed 27 May 2013
93. Available from: Http://www.phynova. com/Research-Development-Obesity.asp [Last accessed 27 May 2013
94. Available from: Http://www. alplifesciences.com/News.aspx [Last accessed 27 May 2013
95. Iwasaki T, Yoneda M, Inamori M, et al. Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology 2011;58(112):2103-5
96. Hotta K, Yoneda M, Hyogo H, et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet 2010;11:172
97. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53(6):1883-94
98. Kitamoto T, Kitamoto A, Yoneda M, et al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet 2013; published online 28 March 2013
99. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009;7:234-8